Filing Details

Accession Number:
0001179110-20-010865
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-11-06 16:27:23
Reporting Period:
2020-11-04
Accepted Time:
2020-11-06 16:27:23
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1070081 Ptc Therapeutics Inc. PTCT Pharmaceutical Preparations (2834) 043416587
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1578850 Gregory Neil Almstead C/O Ptc Therapeutics, Inc.
100 Corporate Court
South Plainfield NJ 07080
Chief Technical Ops Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-11-04 2,187 $11.23 29,276 No 4 M Direct
Common Stock Disposition 2020-11-04 2,187 $60.00 27,089 No 4 S Direct
Common Stock Acquisiton 2020-11-04 21,875 $11.23 48,964 No 4 M Direct
Common Stock Disposition 2020-11-04 21,875 $60.00 27,089 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right To Buy) Disposition 2020-11-04 2,187 $11.23 2,187 $11.23
Common Stock Stock Option (Right to Buy) Disposition 2020-11-04 21,875 $11.23 21,875 $11.23
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
32,813 2027-01-02 No 4 M Direct
10,938 2027-01-02 No 4 M Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Stock Option (Right To Buy) $490.80 2021-04-27 216 216 Direct
Common Stock Stock Option (Right To Buy) $218.40 2022-01-10 166 166 Direct
Common Stock Stock Option (Right To Buy) $27.05 2024-01-27 40,000 40,000 Direct
Common Stock Stock Option (Right To Buy) $51.00 2025-01-01 69,550 69,550 Direct
Common Stock Stock Option (Right To Buy) $30.86 2026-01-03 55,000 55,000 Direct
Common Stock Stock Option (Right To Buy) $18.01 2028-01-02 70,000 70,000 Direct
Common Stock Stock Option (Right To Buy) $33.02 2029-01-21 72,500 72,500 Direct
Common Stock Stock Option (Right To Buy) $33.02 2029-01-21 17,500 17,500 Direct
Common Stock Stock Option (Right To Buy) $51.16 2030-01-28 69,500 69,500 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2021-04-27 216 216 Direct
2022-01-10 166 166 Direct
2024-01-27 40,000 40,000 Direct
2025-01-01 69,550 69,550 Direct
2026-01-03 55,000 55,000 Direct
2028-01-02 70,000 70,000 Direct
2029-01-21 72,500 72,500 Direct
2029-01-21 17,500 17,500 Direct
2030-01-28 69,500 69,500 Direct
Footnotes
  1. The transactions reported in this Form 4 were effected pursuant to written a Rule 10b5-1 plan adopted by the Reporting Person on August 16, 2019.
  2. This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018.
  3. Currently exercisable.
  4. This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019.
  5. This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020.
  6. This option was granted on January 22, 2019 and vests over four years, with 50% of the shares underlying the option vesting on January 22, 2022, and the remaining 50% of the original number of shares underlying the option vesting on January 22, 2023.
  7. This option was granted on January 29, 2020, and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 29, 2021.